Nanomedicine systems aim to improve the biodistribution and the target site accumulation of
systemically applied (chemo-) therapeutics. By increasing drug localization at the …

We review recent progress in polymer‐drug conjugate for cancer nanomedicine. Polymer‐
drug conjugates, including the nanoparticle prepared from these conjugates, are designed …

It is almost four decades since N-(2-hydroxypropyl) methacrylamide (HPMA)-based
copolymers arose as drug carriers. Although fundamentals have been established and …

Endosomal pH-activatable doxorubicin (DOX) prodrug nanogels were designed, prepared,
and investigated for triggered intracellular drug release in cancer cells. DOX prodrugs with …

Over the past few decades, numerous polymer drug carrier systems are designed and
synthesized, and their properties are evaluated. Many of these systems are based on water …

Copolymers based on N-(2-hydroxypropyl) methacrylamide (HPMA) are prototypic and well-
characterized polymeric drug carriers that have been broadly implemented in the delivery of …

PEGylation is the covalent conjugation of PEG to therapeutic molecules. Protein PEGylation
is a clinically proven approach for extending the circulation half-life and reducing the …

Combination chemotherapy treatments with polymer drug conjugates (PDCs) have been
designed to overcome the limitations of traditional chemotherapy. While there are many …

Nanomedicine allows achievement of tumor-selective drug delivery because of the
enhanced permeability and retention (EPR) effect of solid tumors. We report here the first …

In recent decades, nanoparticles have shown significant promise as an oncology treatment
modality. Responsive polymers represent a promising class of nanoparticles that can trigger …